New hope for malaria treatment as drug resistance found unable to spread for the first time

Resistance to a key anti-malarial drug cannot be passed on by mosquitoes in a breakthrough scientists believe could drastically improve the way we battle the disease. 

The discovery could potentially shut down the avenue for mass drug resistance to spread, making malaria treatment significantly more effective for the 3.2 billion people at risk.

The international research project was led by the University of Melbourne and focused on the drug atovaquone. Atovaquone was introduced in 2000 and is safe for pregnant women and children, so it is one of the few anti-malarials that can be used in mass administration approaches.

It was largely phased out of use because resistance was initially observed. But as published in the journal Science today, the new study reveals that although some malaria parasites had developed a genetic mutation that protected them against the drug in early life, the mutation eventually killed the parasites by stopping production of an essential type of energy as they grew.

Lead authors Professor Geoff McFadden and Dr Dean Goodman are calling it a 'genetic trap' that could prove to be a significant step forward in the anti-malaria fight. The pair, along with long-term collaborator Vanessa Mollard, led a team investigating the evolution and life cycle of the malaria parasite for the past six years.

"These results are very exciting because the spread of drug resistance is currently destroying our ability to control malaria," said Prof McFadden from the School of Biosciences at the University of Melbourne.

"We now understand the particular genetic mutation that gave rise to drug resistance in some malaria parasite populations and how it eventually kills them in the mosquito, providing new targets for the development of drugs."